The first patient has been enrolled in part three of the Phase I study of sudocetaxel zendusortide for advanced ovarian cancer. Credit: Chinnapong / Shutterstock.com.

Theratechnologies has dosed the first subject in part three of its Phase I clinical study of sudocetaxel zendusortide for advanced ovarian cancer.

After the antitumor activity was demonstrated in parts one and two, the company enrolled the first patient in part three.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The announcement comes after the US Food and Drug Administration (FDA) accepted the company’s amended protocol for the Phase I trial in June this year.

The updated protocol is designed to enhance sudocetaxel zendusortide’s therapeutic window and prolong the duration of treatment.

Upon the establishment of initial dose safety in the first six subjects, the trial intends to enrol a total of 16 patients in part three.

See Also:

Sudocetaxel zendusortide, an investigational, first-in-class peptide-drug conjugate, is designed to target sortilin. It boosts the internalisation and delivery of a cytotoxic payload into cancer cells directly.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It received fast-track designation from the FDA as a monotherapy to treat all sortilin-positive recurrent advanced solid tumours that are refractory to standard therapy.

Theratechnologies senior vice-president and chief medical officer Christian Marsolais said: “We are excited to dose the first of six patients in part three of the Phase 1 trial of sudocetaxel zendusortide with its modified design and dosing regimen.

“We look forward to building on the efficacy we’ve observed so far, which is mainly long-term disease stabilisation in a number of advanced patients. This first-patient-dosed milestone thus extends the momentum of our oncology clinical development programme.”